Allurion Reports Second Quarter 2025 Financial Results and Provides Business Update
ALURNATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the second quarter and provided a business update. Recent Company Highlights and Outlook Announced new strategic direction focused on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry Signed term sheet with strategic partner to enhance manufacturing and distribution capabilities and R&D pipeline,
Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025
ALURNATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
ALURNATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a new strategic direction with an increasing focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and US market entry. The company has reported on real-world data from nearly 20,000 patients that demonstrate that patients using the Allurion Program lose weight immediately and through a focus on behavior change, keep the weight off while incre
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
ALURNATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting. This data include findings from a global, real-world experience evaluating body composition outcomes that demonstrate sustained weight loss, significant fat loss, and preservation of muscle mass with the Allurion Program and one of the longest real-wor
10 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session
ALURAllurion Technologies Presents Study On Increasing Muscle Mass And Decreasing Fat Mass In Patients Treated With Allurion Program At SOFFCO.MM
ALUR12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session
ALURAllurion Technologies Q1 Adj. EPS $0.24 Beats $(8.58) Estimate, Sales $5.58M Beat $5.50M Estimate
ALURAllurion Technologies Affirms FY2025 Sales Guidance of $30.00M vs $40.20M Est
ALUREarnings Outlook For Allurion Technologies
ALUR11 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session
ALUR12 Consumer Discretionary Stocks Moving In Monday's After-Market Session
ALURAllurion Postpones Special Meeting Of Stockholders From April 4, 2025 To April 10, 2025
ALURChardan Capital Maintains Neutral on Allurion Technologies, Maintains $2.5 Price Target
ALURAllurion Technologies Sees 2025 Revenue Guidance Of Approximately $30M With A Reduction Of Approximately 50% In Operating Expenses Compared To 2024
ALURAllurion Technologies Q4 2024 GAAP EPS $(7.95), Sales $5.591M Miss $5.825M Estimate
ALUREarnings Scheduled For March 26, 2025
ALURGold Down Over 1%; Micron Technology Shares Fall After Q2 Earnings
ALURRoth MKM Reiterates Buy on Allurion Technologies, Maintains $16 Price Target
ALURDow Tumbles Over 400 Points; Nike Shares Dip After Q3 Results
ALURChardan Capital Maintains Neutral on Allurion Technologies, Announces $2.5 Price Target
ALURMarket-Moving News for March 21st
ALURWhy Ouster Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
ALURAllurion Announces Initial Results On Combination Of Allurion Program With Low-Dose GLP-1 Therapy To Optimize Muscle Mass And GLP-1 Adherence
ALURAllurion Announces Notification Of Issuance Of US Patents Titled 'Automatic-Sealing Balloon-Filling Catheter System' And 'Balloon Sealing and Fill Valve'
ALURDow Dips 150 Points; US Housing Starts Fall In January
ALURAllurion To Raise ~$6.1M In Offering And Concurrent Private Placement Of 900,000 At 5.23/Share
ALURAllurion Technologies Announces New Study On Allurion Balloon And GLP-1 Agonists To Boost Long-Term Tolerability And Adherence; Previous Studies Show 30% GLP-1 Discontinuation in First Month, 58% Overall
ALURAllurion Announces Resumption Of Allurion Balloon Sales In France After ANSM Clearance; Planning Clinical Trial On Combination Therapy With GLP-1s To Prevent Muscle Loss
ALURAllurion Technologies Sees Prelim. Q4 Revenue ~$5.6M Vs $5.575M Est.
ALURAllurion Announces $2.5M Private Placement Of 841,751 Shares At $2.97/Share
ALURAllurion Technologies Announces 1-for-25 Reverse Stock Split Effective January 3
ALUR12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session
ALURChardan Capital Downgrades Allurion Technologies to Neutral
ALURAllurion Technologies Announced Data From Over 19,000 Patients Between 2018-2023 That Used Its Program Showing An Average Loss Of 12.2% Of Total Body Weight
ALURAllurion Presents The Second Abstract Reports On Outcomes Of The Allurion Program For 27 Patients Previously Treated With Liraglutide Who Did Not Respond To Their GLP-1 Treatment. 55% Had No Weight Loss And 45% Had Weight Loss Of Less Than 5% With GLP-1 M
ALUR